ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced the start of a multicenter, single arm Phase 2 investigator-sponsored study of palifosfamide (ZIO-201) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE